ILMN News & Events

Illumina (ILMN) and Labcorp (LH) announced an expanded collaboration to advance precision oncology through applications of next-generation sequencing solutions across the healthcare ecosystem. Projects are expected to include promoting equitable access to cancer biomarker testing by bringing it closer to patients through new distributed test offerings; generating evidence to facilitate payer coverage; and developing new tests to address areas of unmet need.

Illumina announced a strategic collaboration with Veritas Genetics Powered By Fuze Health to form a consortium that aims to bring preventive genomics into everyday healthcare through health insurance plans in the United States and under other global markets, setting a new standard for proactive health management. By combining clinical-grade sequencing, advanced informatics, and member-ready reporting, the collaboration supports an integrated data ecosystem to advance research, drug discovery, and clinical trial optimization. "The myGenome whole-genome sequencing comprehensive genetic risk service has been developed to integrate into a health insurer's environment and enable members to benefit from preventive genomics at a personalized level," said Javier de Echevarria, CEO, Veritas Genetics and Chief Genomics Officer, Fuze Health.

Illumina announced the launch of TruPath Genome. Illumina said: "TruPath Genome has been found to deliver unparalleled accuracy and resolution-even across so-called 'dark regions' of the genome-providing researchers with a more complete picture of genomic alterations implicated in genetic disease." TruPath Genome delivers a whole genome workflow solution at a $395 USD list price.